PARP inhibitor-induced senescence leads to the sensitivity of breast and ovarian cancer cells to second-phase synthetic lethal interaction by using senolytic agents to target the senescence state, increasing the combination therapy efficacy in the xenografted breast (MDA-MB-231) and ovarian (OV4453, OV1946) cancer models [68]. The gene discussed is PARP1; the disease is ovarian cancer.